Protocol AML-MM-2000 treatment results of unfavorable prognostic group in children with acute myeloid leukemia
Protocol AML-MM-2000 treatment results of unfavorable prognostic group in children with primary acute myeloid leukemia (AML) in Russia and Belarus are presented. 105 children at the age from 2 weeks till 18 years (a median age — 10.8 years) are included in the study. In 91 patients (86.7%) hematolog...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2022-11-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/645 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850024459197480960 |
|---|---|
| author | N. P. Kirsanova O. V. Aleinikova A. M. Kustanovich T. V. Savitskay R. I. Yutskevich E. V. Volochnik L. V. Baidun Yu. E. Mareiko Yu. S. Strongin N. V. Minakovskay N. V. Migal I. V. Proleskovskay I. V. Emelyanova O. V. Karas A. G. Drekov M. M. Maschan D. V. Litvinov N. V. Myakova E. V. Skorobogatova D. D. Baidildina I. I. Kalinina G. G. Solopova E. V. Suntsova U. N. Petrova L. A. Hachatryan M. M. Scheider A. A. Maschan |
| author_facet | N. P. Kirsanova O. V. Aleinikova A. M. Kustanovich T. V. Savitskay R. I. Yutskevich E. V. Volochnik L. V. Baidun Yu. E. Mareiko Yu. S. Strongin N. V. Minakovskay N. V. Migal I. V. Proleskovskay I. V. Emelyanova O. V. Karas A. G. Drekov M. M. Maschan D. V. Litvinov N. V. Myakova E. V. Skorobogatova D. D. Baidildina I. I. Kalinina G. G. Solopova E. V. Suntsova U. N. Petrova L. A. Hachatryan M. M. Scheider A. A. Maschan |
| author_sort | N. P. Kirsanova |
| collection | DOAJ |
| description | Protocol AML-MM-2000 treatment results of unfavorable prognostic group in children with primary acute myeloid leukemia (AML) in Russia and Belarus are presented. 105 children at the age from 2 weeks till 18 years (a median age — 10.8 years) are included in the study. In 91 patients (86.7%) hematological remission have reached, from them 34 patients (37.4%) are in the first continuous complete remission (CCR). 6-years overall survival (OS), event-free survival (EFS) and relapse-free survival (RFS) rate for all group of patients was 0.35 ±} 0.05; 0.32 ±} 0.04 and 0.43 ±} 0.05, respectively. Survival analysis of children with different cytogenetic anomalies has allowed to define two prognostic groups of patients: the intermediate prognosis, including patients with normal kariotype and t(9;11) which EFS and RFS rate was 40—50%, and unfavorable prognosis with EFS and RFS rate less than 40%. The efficiency analysis of three postremission therapy type (allogeneic and autological hematopoietic stem cells transplantation (HSCT) and chemotherapy (HT)) in intermediate and unfavorable prognostis groups was carried out. High efficiency of related HLA-identical HSCT in patients both intermediate and unfavorable prognostis groups have been shown. Autological HSCT is possible in intermediate prognosis patients with absence of HLA-identical siblings and in unfavorable prognosis patients with absence of HLA-identical unrelated donor. |
| format | Article |
| id | doaj-art-b5947a60a3844a338c3bdb12bb102b9d |
| institution | DOAJ |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| publishDate | 2022-11-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj-art-b5947a60a3844a338c3bdb12bb102b9d2025-08-20T03:01:06ZrusABV-pressОнкогематология1818-83462413-40232022-11-010151310.17650/1818-8346-2009-0-1-5-13523Protocol AML-MM-2000 treatment results of unfavorable prognostic group in children with acute myeloid leukemiaN. P. Kirsanova0O. V. Aleinikova1A. M. Kustanovich2T. V. Savitskay3R. I. Yutskevich4E. V. Volochnik5L. V. Baidun6Yu. E. Mareiko7Yu. S. Strongin8N. V. Minakovskay9N. V. Migal10I. V. Proleskovskay11I. V. Emelyanova12O. V. Karas13A. G. Drekov14M. M. Maschan15D. V. Litvinov16N. V. Myakova17E. V. Skorobogatova18D. D. Baidildina19I. I. Kalinina20G. G. Solopova21E. V. Suntsova22U. N. Petrova23L. A. Hachatryan24M. M. Scheider25A. A. Maschan26Republic Centre for Paediatric Oncology and HaematologyRepublic Centre for Paediatric Oncology and HaematologyRepublic Centre for Paediatric Oncology and HaematologyRepublic Centre for Paediatric Oncology and HaematologyRepublic Centre for Paediatric Oncology and HaematologyRepublic Centre for Paediatric Oncology and HaematologyRussian Children Clinical HospitalRepublic Centre for Paediatric Oncology and HaematologyRepublic Centre for Paediatric Oncology and HaematologyRepublic Centre for Paediatric Oncology and HaematologyRepublic Centre for Paediatric Oncology and HaematologyRepublic Centre for Paediatric Oncology and HaematologyRepublic Centre for Paediatric Oncology and HaematologyRepublic Centre for Paediatric Oncology and HaematologyRepublic Centre for Paediatric Oncology and HaematologyFederal Research Center of Pediatric Hematology, Oncology and Immunology; Russian Children Clinical HospitalFederal Research Center of Pediatric Hematology, Oncology and Immunology; Russian Children Clinical HospitalFederal Research Center of Pediatric Hematology, Oncology and Immunology; Russian Children Clinical HospitalFederal Research Center of Pediatric Hematology, Oncology and Immunology; Russian Children Clinical HospitalRussian Children Clinical HospitalRussian Children Clinical HospitalRussian Children Clinical HospitalRussian Children Clinical HospitalRussian Children Clinical HospitalRussian Children Clinical HospitalFederal Research Center of Pediatric Hematology, Oncology and ImmunologyFederal Research Center of Pediatric Hematology, Oncology and ImmunologyProtocol AML-MM-2000 treatment results of unfavorable prognostic group in children with primary acute myeloid leukemia (AML) in Russia and Belarus are presented. 105 children at the age from 2 weeks till 18 years (a median age — 10.8 years) are included in the study. In 91 patients (86.7%) hematological remission have reached, from them 34 patients (37.4%) are in the first continuous complete remission (CCR). 6-years overall survival (OS), event-free survival (EFS) and relapse-free survival (RFS) rate for all group of patients was 0.35 ±} 0.05; 0.32 ±} 0.04 and 0.43 ±} 0.05, respectively. Survival analysis of children with different cytogenetic anomalies has allowed to define two prognostic groups of patients: the intermediate prognosis, including patients with normal kariotype and t(9;11) which EFS and RFS rate was 40—50%, and unfavorable prognosis with EFS and RFS rate less than 40%. The efficiency analysis of three postremission therapy type (allogeneic and autological hematopoietic stem cells transplantation (HSCT) and chemotherapy (HT)) in intermediate and unfavorable prognostis groups was carried out. High efficiency of related HLA-identical HSCT in patients both intermediate and unfavorable prognostis groups have been shown. Autological HSCT is possible in intermediate prognosis patients with absence of HLA-identical siblings and in unfavorable prognosis patients with absence of HLA-identical unrelated donor.https://oncohematology.abvpress.ru/ongm/article/view/645childrenacute myeloid leukemiaintermediate and unfavorable prognosissurvivalhematopoietic stem cells transplantation |
| spellingShingle | N. P. Kirsanova O. V. Aleinikova A. M. Kustanovich T. V. Savitskay R. I. Yutskevich E. V. Volochnik L. V. Baidun Yu. E. Mareiko Yu. S. Strongin N. V. Minakovskay N. V. Migal I. V. Proleskovskay I. V. Emelyanova O. V. Karas A. G. Drekov M. M. Maschan D. V. Litvinov N. V. Myakova E. V. Skorobogatova D. D. Baidildina I. I. Kalinina G. G. Solopova E. V. Suntsova U. N. Petrova L. A. Hachatryan M. M. Scheider A. A. Maschan Protocol AML-MM-2000 treatment results of unfavorable prognostic group in children with acute myeloid leukemia Онкогематология children acute myeloid leukemia intermediate and unfavorable prognosis survival hematopoietic stem cells transplantation |
| title | Protocol AML-MM-2000 treatment results of unfavorable prognostic group in children with acute myeloid leukemia |
| title_full | Protocol AML-MM-2000 treatment results of unfavorable prognostic group in children with acute myeloid leukemia |
| title_fullStr | Protocol AML-MM-2000 treatment results of unfavorable prognostic group in children with acute myeloid leukemia |
| title_full_unstemmed | Protocol AML-MM-2000 treatment results of unfavorable prognostic group in children with acute myeloid leukemia |
| title_short | Protocol AML-MM-2000 treatment results of unfavorable prognostic group in children with acute myeloid leukemia |
| title_sort | protocol aml mm 2000 treatment results of unfavorable prognostic group in children with acute myeloid leukemia |
| topic | children acute myeloid leukemia intermediate and unfavorable prognosis survival hematopoietic stem cells transplantation |
| url | https://oncohematology.abvpress.ru/ongm/article/view/645 |
| work_keys_str_mv | AT npkirsanova protocolamlmm2000treatmentresultsofunfavorableprognosticgroupinchildrenwithacutemyeloidleukemia AT ovaleinikova protocolamlmm2000treatmentresultsofunfavorableprognosticgroupinchildrenwithacutemyeloidleukemia AT amkustanovich protocolamlmm2000treatmentresultsofunfavorableprognosticgroupinchildrenwithacutemyeloidleukemia AT tvsavitskay protocolamlmm2000treatmentresultsofunfavorableprognosticgroupinchildrenwithacutemyeloidleukemia AT riyutskevich protocolamlmm2000treatmentresultsofunfavorableprognosticgroupinchildrenwithacutemyeloidleukemia AT evvolochnik protocolamlmm2000treatmentresultsofunfavorableprognosticgroupinchildrenwithacutemyeloidleukemia AT lvbaidun protocolamlmm2000treatmentresultsofunfavorableprognosticgroupinchildrenwithacutemyeloidleukemia AT yuemareiko protocolamlmm2000treatmentresultsofunfavorableprognosticgroupinchildrenwithacutemyeloidleukemia AT yusstrongin protocolamlmm2000treatmentresultsofunfavorableprognosticgroupinchildrenwithacutemyeloidleukemia AT nvminakovskay protocolamlmm2000treatmentresultsofunfavorableprognosticgroupinchildrenwithacutemyeloidleukemia AT nvmigal protocolamlmm2000treatmentresultsofunfavorableprognosticgroupinchildrenwithacutemyeloidleukemia AT ivproleskovskay protocolamlmm2000treatmentresultsofunfavorableprognosticgroupinchildrenwithacutemyeloidleukemia AT ivemelyanova protocolamlmm2000treatmentresultsofunfavorableprognosticgroupinchildrenwithacutemyeloidleukemia AT ovkaras protocolamlmm2000treatmentresultsofunfavorableprognosticgroupinchildrenwithacutemyeloidleukemia AT agdrekov protocolamlmm2000treatmentresultsofunfavorableprognosticgroupinchildrenwithacutemyeloidleukemia AT mmmaschan protocolamlmm2000treatmentresultsofunfavorableprognosticgroupinchildrenwithacutemyeloidleukemia AT dvlitvinov protocolamlmm2000treatmentresultsofunfavorableprognosticgroupinchildrenwithacutemyeloidleukemia AT nvmyakova protocolamlmm2000treatmentresultsofunfavorableprognosticgroupinchildrenwithacutemyeloidleukemia AT evskorobogatova protocolamlmm2000treatmentresultsofunfavorableprognosticgroupinchildrenwithacutemyeloidleukemia AT ddbaidildina protocolamlmm2000treatmentresultsofunfavorableprognosticgroupinchildrenwithacutemyeloidleukemia AT iikalinina protocolamlmm2000treatmentresultsofunfavorableprognosticgroupinchildrenwithacutemyeloidleukemia AT ggsolopova protocolamlmm2000treatmentresultsofunfavorableprognosticgroupinchildrenwithacutemyeloidleukemia AT evsuntsova protocolamlmm2000treatmentresultsofunfavorableprognosticgroupinchildrenwithacutemyeloidleukemia AT unpetrova protocolamlmm2000treatmentresultsofunfavorableprognosticgroupinchildrenwithacutemyeloidleukemia AT lahachatryan protocolamlmm2000treatmentresultsofunfavorableprognosticgroupinchildrenwithacutemyeloidleukemia AT mmscheider protocolamlmm2000treatmentresultsofunfavorableprognosticgroupinchildrenwithacutemyeloidleukemia AT aamaschan protocolamlmm2000treatmentresultsofunfavorableprognosticgroupinchildrenwithacutemyeloidleukemia |